噁唑烷酮类抗结核药物的应用开发现状与展望  

Status of Application and Development and Prospect of Oxazolidinone Antituberculosis Drugs

作　　者：陆宇 LU Yu(Pharmacology Research Lab,Beijing Chest Hospital,Capital Medical University,Beijing 101125,China)

机构地区：[1]首都医科大学附属北京胸科医院药物学研究室,北京101125

出　　处：《抗感染药学》2023年第10期1013-1017,1024,共6页Anti-infection Pharmacy

基　　金：国家自然科学基金(编号:81973367,82173862);北京市医院管理中心临床医学发展专项(编号:ZYLX202123);北京市医院管理中心“登峰”人才培养计划(编号:DFL20221402)。

摘　　要：噁唑烷酮类药物是一类对革兰阳性病原菌具有较强抗菌活性的抗菌药物,其中许多噁唑烷酮类化合物对结核分枝杆菌亦有良好的抗菌活性,而如利奈唑胺更是对耐药甚至耐多药结核病有着较好的治疗作用。然而,利奈唑胺的骨髓抑制作用在一定程度上限制了其在抗结核治疗中的广泛应用,因而高效、低毒的噁唑烷酮类抗结核药物的研发备受重视。本文主要就利奈唑胺的抗结核临床应用和其他噁唑烷酮类药物的临床开发现状进行了阐释,以加深对噁唑烷酮类药物抗结核作用的认识。Oxazolidinones are a class of antibacterial drugs with strong antibacterial activity against gram-positive pathogens,and many of them also have good antibacterial activity against Mycobacterium tuberculosis,and linezolid,for example,has good therapeutic effect on drug-resistant or even multi-drug resistant tuberculosis.However,the myosuppressive effect of linezolid limits its wide application in anti-tuberculosis therapy to some extent,so the research and development of highly effective and low-toxicity oxazolidinones has attracted much attention.In this paper,the clinical application of linezolid in anti-tuberculosis and the clinical development status of other oxazolidinones are reviewed,so as to deepen the understanding of the anti-tuberculosis effect of oxazolidinones.

关 键 词：噁唑烷酮类药物 利奈唑胺 新型抗结核药物 开发现状 

分 类 号：R978.3[医药卫生—药品]